An effective treatment in mice to prevent both metastasis and recurrence of breast cancer is about to enter phase 2 clinical trials. This major discovery was made by Belgian researchers.
By Anne-Sophie Leurquin
Lhe promise of a major therapeutic advance in the treatment of breast cancer – and, potentially, other cancers – has just been published this Tuesday in the scientific journal Cancers. And, kidding, it was Belgian researchers from UCLouvain who made this discovery, after seven years of research thanks to the continued support of the Fondation Louvain, the FRS-FNRS, the Fondation contre le Cancer and the Televie.
The research team, led by Professor Pierre Sonveaux, has uncovered the preventive action of a drug which blocks the recurrence and spread of metastases of human breast cancer in mice. MitoQ (from the New Zealand laboratory Antipodean Pharmaceuticals) was then administered at the desired doses to healthy volunteers during a phase 1 clinical trial. Its toxicity is low, with the exception of nausea and vomiting at high doses.
With this offer, enjoy:
-
Unlimited access to all the articles, files and reports of the editorial staff -
The newspaper in digital version -
Reading comfort with limited advertising
–
–
